AU2002323543A1 - Compositions and methods of use of targeting peptides against placenta and adipose tissues - Google Patents

Compositions and methods of use of targeting peptides against placenta and adipose tissues

Info

Publication number
AU2002323543A1
AU2002323543A1 AU2002323543A AU2002323543A AU2002323543A1 AU 2002323543 A1 AU2002323543 A1 AU 2002323543A1 AU 2002323543 A AU2002323543 A AU 2002323543A AU 2002323543 A AU2002323543 A AU 2002323543A AU 2002323543 A1 AU2002323543 A1 AU 2002323543A1
Authority
AU
Australia
Prior art keywords
compositions
methods
adipose tissues
targeting peptides
peptides against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002323543A
Inventor
Wadih Arap
Mikhail G. Kolonin
Renata Pasqualini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/027692 external-priority patent/WO2002020769A1/en
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU2002323543A1 publication Critical patent/AU2002323543A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/28—Gramicidins A, B, D; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2002323543A 2001-09-07 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues Abandoned AU2002323543A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2001/027692 WO2002020769A1 (en) 2000-09-08 2001-09-07 Human and mouse targeting peptides identified by phage display
AUPCT/US2001/027692 2001-09-07
PCT/US2002/027836 WO2003022991A2 (en) 2001-09-07 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues

Publications (1)

Publication Number Publication Date
AU2002323543A1 true AU2002323543A1 (en) 2003-03-24

Family

ID=21742817

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002323543A Abandoned AU2002323543A1 (en) 2001-09-07 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues

Country Status (4)

Country Link
EP (1) EP1497314A4 (en)
AU (1) AU2002323543A1 (en)
CA (1) CA2458047A1 (en)
WO (1) WO2003022991A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2005041882A2 (en) * 2003-10-31 2005-05-12 The Burnham Institute Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
US20050191294A1 (en) * 2003-12-31 2005-09-01 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2007020405A2 (en) * 2005-08-12 2007-02-22 Cartela R & D Ab Integrin i-domain binding peptides
CN103458911B (en) 2011-02-11 2016-02-24 密歇根大学董事会 Peptide combinations and the method being used for the treatment of patient
JP2018501195A (en) * 2014-11-03 2018-01-18 清華大学Ｔｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ Drugs to inhibit adipocyte differentiation and insulin resistance
CN114469891B (en) * 2021-12-29 2023-01-24 中山大学附属第一医院 Micromolecule drug/therapeutic gene combined delivery system with enzyme sensitive shell and preparation method and application thereof
CN114272390B (en) * 2021-12-29 2022-09-02 中山大学附属第一医院 Microenvironment targeted combined cell targeted tumor inhibition carrier and preparation method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
DE19605175A1 (en) * 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipid compounds and their use
CA2283474A1 (en) * 1997-03-04 1998-09-11 Bio-Technology General Corp. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
FR2797689B1 (en) * 1999-08-16 2003-06-27 Pasteur Sanofi Diagnostics USE OF SYNTHETIC COMPOUNDS FOR IMMUNODAYS
GB9929471D0 (en) * 1999-12-13 2000-02-09 Proteom Ltd Complementary peptide ligande generated from higher eukaryote genome sequences
EP1250355A1 (en) * 2000-01-21 2002-10-23 The Burnham Institute Chimeric prostate-homing peptides with pro-apoptotic activity
AU2001290652A1 (en) * 2000-09-08 2002-03-22 Board Of Regents, The University Of Texas System Methods and compositions for in vitro targeting

Also Published As

Publication number Publication date
EP1497314A4 (en) 2007-10-10
EP1497314A2 (en) 2005-01-19
WO2003022991A2 (en) 2003-03-20
CA2458047A1 (en) 2003-03-20
WO2003022991A3 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
AU2003249606A1 (en) Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof
AU2002230831A1 (en) Compositions of human proteins and method of use thereof
AU2002252025A1 (en) Injection molding of living tissues
AU2002254328A1 (en) Inhibitors and disassemblers of fibrillogenesis
AU3887900A (en) Protamine fragment compositions and methods of use
AU2001234437A1 (en) Deicing compositions and methods of use
AU2002323543A1 (en) Compositions and methods of use of targeting peptides against placenta and adipose tissues
AU2003301240A1 (en) Skin cleanser compositions and methods of use
AU2002330556A1 (en) Cosmetic or dermatological use of peptides for promoting adhesion between skin cells
AU2002367903A1 (en) Biologic-chemical herbicide compositions and methods of use
AU2002350079A1 (en) Gel composition and methods of use
AU2002343601A1 (en) Proteins involved in regulation of adipocytes and uses related thereto
AU5487699A (en) Adhesive compositions for the hard tissues of the human body
WO2001091700A8 (en) Composition and method for enhancing elasticity of tissue
AU2002362118A1 (en) Compositions and methods for high sorption of skin materials and delivery of sulfur
AU2002251999A1 (en) Methods and compositions for the construction and use of fusion libraries using computational protein design methods
AU2003241103A1 (en) Compositions containing anti-hiv peptides and methods of use
AU2002364501A1 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2002339904A1 (en) Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
AU2003215264A1 (en) Compositions and methods for delivery of skin cosmeceuticals
AU2003246614A8 (en) Novel use of lipopeptide preparations
AU2002242111A1 (en) Frozen biocidal compositions and methods of use thereof
AU2002311620A1 (en) Methods of making and using expression constructs for the expression of recombinant proteins
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2001271281A1 (en) Novel compositions for the expression of the human peptide histidine transporter1 and methods of use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase